Oncotarget

Research Papers:

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

miR-590 promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia by inhibiting RB1

Mei-hua Miao _, Xue-qiang Ji, Hao Zhang, Jun Xu, Hong Zhu and Xue-jun Shao

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:39527-39534. https://doi.org/10.18632/oncotarget.8414

Metrics: PDF 1137 views  |   HTML 2508 views  |   ?  


Abstract

Mei-hua Miao1,*, Xue-qiang Ji1,*, Hao Zhang2,*, Jun Xu1, Hong Zhu1, Xue-jun Shao1

1Department of Clinical Laboratory Diagnosis, Children’s Hospital of Soochow University, Suzhou, China

2Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, China

*These authors have contributed equally to this work

Correspondence to:

Xue-jun Shao, email: [email protected]

Keywords: miR-590, RB1, T-ALL, cancer

Received: January 28, 2016     Accepted: March 02, 2016     Published: March 28, 2016

ABSTRACT

MicroRNAs play important roles in the pathogenesis of cancers by inhibiting gene expression at posttranscriptional level. Here, we identified that miR-590 and its predicted target gene RB1 are differentially expressed in T-cell acute lymphoblastic leukaemia (T-ALL). The correlation between miR-590 and RB1 was further confirmed in 395 T-ALL patients. In T-ALL cell lines, miR-590 promoted the cell proliferation by increasing G1/S transition. Moreover, migration and invasion assay showed that miR-590 promotes the migration and invasion of T-ALL cells by increasing E-cadherin and inhibiting MMP-9. Luciferase assays confirmed that miR-590 directly binds to the 3'untranslated region of RB1, and western blotting showed that miR-590 suppresses the expression of RB1 at the protein levels. This study indicated that miR-590 inhibits RB1 and promotes proliferation and invasion of T-ALL cells. Thus, miR-590 may represent a potential therapeutic target for T-ALL intervention.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8414